title: Vildagliptin in patients with type 2 diabetes mellitus and renal impairment.
authors.affiliation: Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
authors.forename: Per-Henrik
authors.initials: PH
authors.lastname: Groop
authors.affiliation: Novartis Pharma AG, Basel, Switzerland. Electronic address: neelesh.dongre@novartis.com.
authors.forename: Neelesh
authors.initials: N
authors.lastname: Dongre
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Kothny
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D001786:Blood Glucose / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D009570:Nitriles / Q000493:pharmacokinetics*; D011759:Pyrrolidines / Q000493:pharmacokinetics*; D051437:Renal Insufficiency / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000077597:Vildagliptin
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D009570:Nitriles; D011759:Pyrrolidines; D003404:Creatinine; D000077597:Vildagliptin; D000218:Adamantane
keywords: Anti-hyperglycaemic agent; Dipeptidyl peptidase-4 inhibitor; Renal impairment; Type 2 diabetes mellitus; Vildagliptin